Daiwa Securities Group Inc. acquired a new position in shares of Bausch Health Companies Inc (NYSE:BHC) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 103,756 shares of the company’s stock, valued at approximately $2,663,000.
Other hedge funds also recently added to or reduced their stakes in the company. Andra AP fonden bought a new position in Bausch Health Companies during the third quarter worth $7,039,000. Marshall Wace LLP bought a new stake in shares of Bausch Health Companies in the second quarter valued at about $2,974,000. NEXT Financial Group Inc bought a new stake in shares of Bausch Health Companies in the third quarter valued at about $101,000. Private Management Group Inc. bought a new stake in shares of Bausch Health Companies in the second quarter valued at about $28,474,000. Finally, Point View Wealth Management Inc. bought a new stake in shares of Bausch Health Companies in the second quarter valued at about $1,132,000. 42.90% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Schutter Richard U. De acquired 125,000 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was acquired at an average price of $23.96 per share, with a total value of $2,995,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joseph C. Papa acquired 30,000 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The shares were purchased at an average cost of $22.32 per share, with a total value of $669,600.00. The disclosure for this purchase can be found here. Insiders have purchased 165,000 shares of company stock valued at $3,890,700 in the last ninety days. 11.54% of the stock is currently owned by company insiders.
Shares of Bausch Health Companies stock opened at $27.20 on Friday. The stock has a market capitalization of $9.48 billion, a PE ratio of 6.87, a price-to-earnings-growth ratio of 0.37 and a beta of -0.28. Bausch Health Companies Inc has a 52-week low of $13.86 and a 52-week high of $28.45. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.14 and a quick ratio of 0.89.
Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.84 by $0.31. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The business had revenue of $2.14 billion during the quarter, compared to analysts’ expectations of $2.09 billion. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. As a group, analysts anticipate that Bausch Health Companies Inc will post 3.7 earnings per share for the current year.
A number of brokerages have recently issued reports on BHC. Zacks Investment Research raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a research report on Wednesday, October 3rd. ValuEngine cut shares of Bausch Health Companies from a “hold” rating to a “sell” rating in a research report on Tuesday, October 2nd. TD Securities boosted their target price on shares of Bausch Health Companies from $24.00 to $28.00 and gave the company a “hold” rating in a research report on Wednesday. Royal Bank of Canada boosted their target price on shares of Bausch Health Companies from $30.00 to $31.00 and gave the company a “hold” rating in a research report on Wednesday. Finally, Mizuho reissued a “buy” rating and issued a $35.00 target price on shares of Bausch Health Companies in a research report on Monday, October 8th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. Bausch Health Companies has a consensus rating of “Hold” and a consensus target price of $27.55.
Bausch Health Companies Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Recommended Story: Preferred Stock
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.